Loading...
Market
Leading AstraZeneca revenue growth portfolio by 2025
5
Resolution / Starting Odds
Oncology • 25%
Biopharmaceuticals • 25%
Rare diseases • 25%
Other • 25%
AstraZeneca financial reports
Story
AstraZeneca Targets $80 Billion Revenue by 2030 with 75% Growth and 20 New Medicines
May 21, 2024, 10:22 AM
AstraZeneca has set an ambitious target to achieve $80 billion in total revenue by 2030, nearly doubling its revenue from the previous year’s $45.81 billion. The British drugmaker plans to launch 20 new medicines by 2030, which are expected to significantly contribute to this growth. CEO Pascal Soriot aims to solidify his legacy through this expansion, which will also be driven by growth in the company's existing oncology, biopharmaceuticals, and rare disease portfolios. This new revenue goal surpasses analyst forecasts and highlights AstraZeneca's confidence in its pipeline, which features several potential $5 billion-plus candidates.
View original story
Similar markets
Oncology • 33%
Biopharmaceuticals • 33%
Rare Diseases • 33%
$50 Billion • 25%
$60 Billion • 25%
$70 Billion • 25%
$80 Billion • 25%
Less than 5 • 25%
5 to 9 • 25%
10 to 14 • 25%
15 or more • 25%
Less than $500 million • 33%
$500 million to $1 billion • 33%
Greater than $1 billion • 34%
Amgen outperforms AstraZeneca • 33%
AstraZeneca outperforms Amgen • 33%
Both perform similarly • 34%
Top 1 • 25%
Top 2 • 25%
Top 3 • 25%
Top 4+ • 25%
Drug A • 25%
Drug B • 25%
Drug C • 25%
Drug D • 25%
